ResearcherUniversitätsmedizin GöttingenActive in the last 2 years
Constanza Tapia Contreras
Matched on ORCID iD 0000-0003-2054-0963; OpenAlex author ID A5000553214. Sources: OpenAlex.
Their work
- Papers
- 5
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 33
2024: 1 paper · 2025: 2 papers · 2026: 2 papers
Papers 5
- The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/mco2.70794↗
- Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.08.018↗
- KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Co-author DOI 10.1002/1878-0261.13725↗
- Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. Co-author DOI 10.1038/s41419-025-08362-w↗
- A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. Co-author DOI 10.1002/advs.202307695↗
Closest collaborators
The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Günter Schneider · 5 shared papers, 2024–2026 · strength 0.92
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w↗
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Elisabeth Heßmann · 5 shared papers, 2024–2026 · strength 0.92
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w↗
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Carolin Schneider · 4 shared papers, 2024–2026 · strength 0.71
- Paper Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells. DOI 10.1038/s41419-025-08362-w↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Christian Schneeweis · 4 shared papers, 2024–2026 · strength 0.71
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Michael B. Ghadimi · 4 shared papers, 2024–2026 · strength 0.71
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Matthias Wirth · 4 shared papers, 2024–2026 · strength 0.71
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Dieter Saur · 4 shared papers, 2024–2026 · strength 0.71
- Paper Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancrea… DOI 10.1053/j.gastro.2025.08.018↗
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Marian Grade · 3 shared papers, 2024–2026 · strength 0.50
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Maximilian Reichert · 3 shared papers, 2024–2026 · strength 0.50
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Lukas Krauß · 3 shared papers, 2024–2026 · strength 0.50
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Volker Ellenrieder · 3 shared papers, 2024–2026 · strength 0.50
- Paper The Protein Phosphatase Inhibitor LB100 Targets the Mesenchymal Lineage of Pancreatic Ductal Adenocarcinoma. DOI 10.1002/mco2.70794↗
- Paper KRAS G 12C-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. DOI 10.1002/1878-0261.13725↗
- Paper A Novel AMPK Inhibitor Sensitizes Pancreatic Cancer Cells to Ferroptosis Induction. DOI 10.1002/advs.202307695↗
- Ulrich Bernd Keller · 2 shared papers, 2026 · strength 0.40
- Hazal Köse · 2 shared papers, 2026 · strength 0.40
- Gabriela Salinas Riester · 2 shared papers, 2025 · strength 0.38
- Felix Orben · 2 shared papers, 2024–2026 · strength 0.33
- Roland Rad · 2 shared papers, 2024–2026 · strength 0.33
- Adi Danieli‐Mackay · 1 shared paper, 2025 · strength 0.21
- Maj-Britt Paulsohn · 1 shared paper, 2025 · strength 0.21
- Matthias Dobbelstein · 1 shared paper, 2025 · strength 0.21
- Oliver Holger Krämer · 1 shared paper, 2026 · strength 0.19
- Roland Michael Schmid · 1 shared paper, 2026 · strength 0.19
- Janine Murr · 1 shared paper, 2026 · strength 0.19
- Alexandra Nguyen · 1 shared paper, 2026 · strength 0.19
- Sebastian Mueller · 1 shared paper, 2026 · strength 0.19
- Tiago De Oliveira · 1 shared paper, 2025 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.